Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Public ClinicalTrials.gov record NCT00963105. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (REVLIMID®) Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and effectiveness of different dose regimens of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Study identification
- NCT ID
- NCT00963105
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 104 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 18, 2009
- Primary completion
- Sep 4, 2017
- Completion
- Sep 4, 2017
- Last update posted
- Oct 30, 2018
2009 – 2017
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Moores Cancer Center | La Jolla | California | 92093-0820 | — |
| Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage | California | 92270 | — |
| Stanford University School of Medicine | Stanford | California | 94305-5821 | — |
| Cancer Center of Central Connecticut | Southington | Connecticut | 06489 | — |
| Cancer and Blood Disease Center | Lecanto | Florida | 34461 | — |
| Northwestern University Medical Center Division of Hematology Oncology | Chicago | Illinois | 60611-2927 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202-5149 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Long Island Jewish Medical Center CLL Research and Treatment Program | New Hyde Park | New York | 11042 | — |
| Wake Forest University School of Medicine | Winston-Salem | North Carolina | 27104 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Drexel University, College of Medicine, Clinical Research Group | Philadelphia | Pennsylvania | 19102 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00963105, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2018 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00963105 live on ClinicalTrials.gov.